BCD-180 (international non-proprietary name: seniprutug) is a monoclonal antibody, an original investigational product for human use being developed for the treatment of radiographic axial spondyloarthritis (ankylosing spondylitis, Bechterew's disease).

A monoclonal antibody is a protein created by scientists in a laboratory, similar to the natural antibodies of the immune system, designed to bind to a specific target in the human body¹.

It is known that a key role in the development and maintenance of inflammation in ankylosing spondylitis is played by a group of specific immune cells of lymphocytes, which have common structural features of one of the receptor sites (a protein that transmits signals from the cell and inside it and ensures the interaction of cells with each other) on the cell surface. This receptor site is called TRBV9 and lymphocytes carrying a receptor with this structure on their surface are called TRBV9+ lymphocytes^2,3,4,5. BCD-180 (international non-proprietary name: seniprutug) specifically binds to TRBV9 on the surface of such lymphocytes and destroys them. In the clinical study, BCD-180 (international non-proprietary name: seniprutug) is administered intravenously. The research physician closely monitors the patient’s condition throughout their participation in the study and will take all necessary actions to manage adverse events if they occur.

In the clinical trial, BCD-180 (international non-proprietary name: seniprutug) is administered intravenously. The physician-investigator closely monitors the patient’s condition throughout their participation in the study and will take all necessary actions to manage adverse events if they occur.

To reduce the risk of adverse reactions, all subjects participating in the clinical trial are given anti-inflammatory and anti-allergic drugs before the administration of BCD-180 (international non-proprietary name: seniprutug).

Breedveld FC. Therapeutic monoclonal antibodies. The Lancet. 2000;355(9205):735–40.
Faham M., Carlton V., Moorhead M., Zheng J., Klinger M., Pepin F., et al. Discovery of T Cell Receptor β Motifs Specific to HLA–B27–Positive Ankylosing Spondylitis by Deep Repertoire Sequence Analysis. Arthritis & Rheumatology. 2017;69(4):774–84.
Mamedov I. Z., Britanova O. V., Chkalina A. V., Staroverov D. B., Amosova A. L., Mishin A. S., et al. Individual characterization of stably expanded T cell clones in ankylosing spondylitis patients. Autoimmunity. 2009;42(6):525–36.
Zheng M., Zhang X., Zhou Y., Tang J., Han Q., Zhang Y., et al. TCR repertoire and CDR3 motif analyses depict the role of αβ T cells in Ankylosing spondylitis. EBioMedicine. 2019;47:414–26.
Komech E. A., Pogorelyy M. V., Egorov E. S., Britanova O. V., Rebrikov D. V., Bochkova A. G., et al. CD8+ T cells with characteristic T cell receptor beta motif are detected in blood and expanded in synovial fluid of ankylosing spondylitis patients. Rheumatology (Oxford). 2018;57(6):1097–104.

This section of the website contains information about an unauthorized investigational medicinal product for medical use.

分子

搜索研究药物

ANB-002

BCD-201

BCD-132

BCD-180